EDAP Edap Tms S.A. ADS

EDAP TMS SA to Announce Fourth Quarter and Year Ended December 31, 2019 Financial Results on Monday, March 30, 2020

EDAP TMS SA to Announce Fourth Quarter and Year Ended December 31, 2019 Financial Results on Monday, March 30, 2020

Company to host conference call and webcast on Tuesday, March 31st @ 8:30 am EDT

LYON, France, March 24, 2020 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2019 after the markets close on Monday, March 30, 2020.

An accompanying conference call and webcast will be conducted by Marc Oczachowski, Chief Executive Officer and François Dietsch, Chief Financial Officer, to review the results. The call will be held at 8:30am EDT on Tuesday, March 31, 2020. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Call & Webcast

Tuesday, March 31st @ 8:30am Eastern Time

Domestic:                    877-451-6152

International:              201-389-0879

Passcode:                    13700921

Webcast:                    

About EDAP TMS SA

A recognized leader in the global therapeutic ultrasound market for almost 40 years, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for urology using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in 2013 in Europe and in 2018 in the US as the answer to all requirements for ideal prostate tissue ablation as a complement to the existing FDA-cleared Ablatherm® Robotic HIFU and Ablatherm® Fusion. As a pioneer and key player in the field of extracorporeal shock wave lithotripsy (ESWL), EDAP TMS exclusively utilizes the latest generation of shock wave source in its Sonolith® range of ESWL systems. For more information on the Company, please visit -tms.com, and us.hifu-prostate.com.

CONTACTS:

Blandine Confort

Investor Relations / Legal Affairs

EDAP TMS SA

50

Investor Contact

Jeremy Feffer

LifeSci Advisors, LLC

212-915-2568

EN
24/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Edap Tms S.A. ADS

 PRESS RELEASE

EDAP Announces Final Results from HIFI Study Comparing Outcomes of Foc...

EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual Meeting LYON, France, April 23, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced that final results from the HIFI Study, the largest clinical trial ever conducted comparing EDAP’s Focal One robotic high intensity focused ultrasound (HIFU) versus radical prostatectomy (RP) for the treatment of prostate cancer, will be presented d...

 PRESS RELEASE

EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results

EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results Record Q4 2023 total revenue of EUR 19.6 million ($21.3 million USD) increased 24.8% over Q4 2022Record Q4 2023 HIFU revenue of EUR 7.5 million ($8.1 million USD), an increase of 38.8% over Q4 2022Record full-year 2023 total revenue of EUR 60.4 million ($65.4 million USD) increased 9.6% over full-year 2022Record full-year 2023 HIFU revenue of EUR 20.6 million ($22.3 million USD), an increase of 31.7% over full-year 2022Strong Q4 2023 U.S. Focal One® HIFU procedure growth of +136% year-over-year Company to host conference call ...

 PRESS RELEASE

EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results o...

EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024 Company to host conference call and webcast on Wednesday, March 27th at 8:30am EDT LYON, France, March 13, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full-year ended December 31, 2023, before the markets open on Wednesday, March 27th, 2024. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chi...

 PRESS RELEASE

EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Se...

EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference LYON, France, March 6, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a virtual presentation and host 1x1 investor meetings at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference, which is being held virtually from March 12-13, 2024. Presentation details: Date:Wednesday, March 13Time:9:20 – 9:50 AM ET Webcast: The live and archived webcast of the ...

 PRESS RELEASE

EDAP Announces FDA Breakthrough Device Designation for Focal One® in t...

EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis Focal One HIFU has potential to address large market impacting thousands of women each year LYON, France, March 4, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that its Focal One platform has been granted Breakthrough Device designation by the US Food and Drug Administration (FDA) for the treatment of deep infiltrating endometriosis (DIE). In June 2018, the FDA cleared Focal One Robotic Focal HIFU for the abl...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch